History Made, as May and Baker Plc Appoints Senator Daisy Danjuma As Non-Executive Director ..............Enter Her Robust Profile
“Women have to find their own personality, their own style, and what suits them the best”-Words of Francois Nars
HISTORY was made last night when globally rated top brand, May and Baker Nigeria Plc officially notified The Nigerian Stock Exchange (The Exchange), the Company’s shareholders and the investing public that Senator Daisy Danjuma is now a Non-Executive Director of the Company.
Danjuma will thus be bringing to the board of the healthcare company more than four decades wealth of experience in legal, administrative and public service.
She is on the board of several companies. She was chairman, South Atlantic Petroleum Limited between 1999 and 2003 and currently the Executive Vice Chairman of the company. Between 2003 and 2007, she served as a Senator of the Federal Republic of Nigeria. As a Senator, she was Chairman, Women and Child Rights Committee of the Economic Community of West African States (ECOWAS), Chairman, Senate Committee on Women Affairs and Youth Development and a member of the Commonwealth Parliamentary Association. She also served as a member of the Senate Committees on Health, Education, Finance, Land and Transport.
SENATOR DAISY: A BRIEF BUT ELABORATE PROFILE
BY MIKE DE CERUTTI
WASAP +234 7042631895
Edo state top philanthropist of global standard, Senator Daisy Ukpomwan Ehanire Danjuma was born on the 6 of August 1952 in Benin City, Edo State. She is a 1976 law graduate of the Ahmadu Bello University Zaria and was called to the Nigerian Bar in 1977. She served her NYSC as a State Counsel in Lagos State Ministry of Justice (DPP) and was a pioneer legal counsel to the Legal Aid Council of Nigeria. She later worked as an Executive Assistant at Nigerian Acceptances Limited (NAL), a Merchant Bank from 1977 to 1978.
FACT ABOUT MAY AND BAKER PLC
May & Baker, Nigeria Plc was founded on September 4, 1944 as Nigeria’s first pharmaceutical company. It has its origin in England, the United Kingdom where in 1834, three chemists founded Grimwade, May & Pickett, a firm for manufacturing chemicals for pharmaceutical products. In 1839 Grimwade, May & Pickett transformed into May & Baker United Kingdom Limited following some changes in the ownership. May & Baker UK Limited transformed into a mega European conglomerate through a web of mergers and acquisitions over years. Consequently the name of the company has changed at different times and today, only the Nigerian offshoot is known by the original name.
In Nigeria the company started as May & Baker (West Africa) Limited at 17A Tinubu Street, Lagos in 1944, a trading outpost to serve the West Coast of Africa. The company relocated to its present site at Ikeja, Lagos state during the Nigerian civil war. In 1976, it built its factory at Ikeja where it began local manufacturing of pharmaceuticals. That same year it changed from May & Baker (West Africa) Limited to May & Baker Nigeria Limited
In 1979, following the indigenisation decree which required that foreign interests in companies operating in Nigeria be of a minority nature, May & Baker, United Kingdom relinquished 60 per cent of its equity holding in May & Baker Nigeria to Nigerians while retaining 40 per cent. The company’s name was changed to Embechem Nigeria Limited but this was dropped later and the name reverted to May & Baker Nigeria Limited.
May & Baker Nigeria Limited became a publicly quoted company following its listing by introduction on the Nigerian Stock Exchange on November 10, 1994 and became May & Baker Nigeria Plc.
For many years expatriates sent by the parent company managed May & Baker Nigeria but in 1997, the first indigenous Managing Director/Chief Executive Officer, Joseph Ikemefuna Odumodu, was appointed.
In 2002 the foreign partners decided to divest. However, represented by Aventis SA, France, they remained technical associates of May & Baker Nigeria Plc. Following the merger of Aventis and Sanofi, another French firm to form Sanofi Aventis in 2004, the technical relationship transferred between May & Baker Nigeria Plc and Sanofi-Aventis of France. But that relationship was renegotiated in 2005 to give May & Baker Nigeria, the leeway to have its own products.
The company thereby began an aggressive expansion and diversification programme since 2005 which has culminated in the creation of new businesses and subsidiaries. In 2005, Biovaccines, a local vaccine production subsidiary was set up in partnership with the Federal Government of Nigeria. In 2006, the company constructed a multi-billion naira food processing factory, constructed a local plant for the production of anti-retroviral drugs in Nigeria while the construction of a World Health Organization Standard Pharmaceutical production facility was constructed and commissioned on June 27, 2011